Compass Therapeutics (NASDAQ:CMPX) Rating Increased to Buy at LADENBURG THALM/SH SH

Compass Therapeutics (NASDAQ:CMPX) was upgraded by research analysts at LADENBURG THALM/SH SH from a “neutral” rating to a “buy” rating in a report issued on Monday, Marketbeat.com reports. The brokerage currently has a $5.00 target price on the stock. LADENBURG THALM/SH SH’s target price would indicate a potential upside of 203.03% from the company’s previous close.

Other research analysts also recently issued reports about the company. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research note on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, August 12th.

Compass Therapeutics Trading Up 7.1 %

Shares of CMPX stock opened at $1.65 on Monday. The business’s 50 day moving average is $1.18 and its two-hundred day moving average is $1.43. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34. The company has a market capitalization of $227.02 million, a P/E ratio of -4.58 and a beta of 0.88.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Monday, August 12th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $0.85 million during the quarter. As a group, equities analysts predict that Compass Therapeutics will post -0.42 earnings per share for the current fiscal year.

Institutional Trading of Compass Therapeutics

Institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC purchased a new stake in shares of Compass Therapeutics in the second quarter valued at approximately $41,000. Panagora Asset Management Inc. purchased a new stake in Compass Therapeutics during the second quarter worth $68,000. Simplicity Wealth LLC purchased a new stake in Compass Therapeutics during the first quarter worth $80,000. Bleakley Financial Group LLC purchased a new stake in Compass Therapeutics during the first quarter worth $80,000. Finally, Ground Swell Capital LLC purchased a new stake in Compass Therapeutics during the second quarter worth $124,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.